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OBJECTIVES The study compared procedural outcomes and long-term survival for patients undergoing
percutaneous coronary intervention (PCI) of a chronic total coronary artery occlusion (CTO) with
a matched non-CTO cohort to determine whether successful PCI of a CTO is associated with
improved survival.
BACKGROUND Percutaneous coronary intervention of a CTO is a common occurrence, and the long-term
survival for patients with successful PCI of a CTO has not been clearly defined.
METHODS Between June 1980 and December 1999, a total of 2,007 consecutive patients underwent PCI
for a CTO. Utilizing propensity scoring methods, a matched non-CTO cohort of 2,007
patients was identified and compared to the CTO group. The cohorts were stratified into
successful and failed procedures.
RESULTS The in-hospital major adverse cardiac event (MACE) rate was 3.8% in the CTO cohort.
Technical success has improved over the last 10 years (overall 74.4%, slope 1.0%/yr, p 5 0.02,
R2 5 49.9%) as did procedural success (overall 69.9%, slope 1.2%/yr, p 5 0.02, R2 5 51.5%)
without a concomitant increase in in-hospital MACE rates (slope 0.1%/yr, p 5 0.7). There
was a distinct 10-year survival advantage for successful CTO treatment compared with failed
CTO treatment (73.5% vs. 65.1%, p 5 0.001). The CTO versus non-CTO 10-year survival
was the same (71.2% vs. 71.4%, p 5 0.9). Diabetics in the CTO cohort had a lower 10-year
survival compared with nondiabetics (58.3% vs. 74.3%, p , 0.0001).
CONCLUSIONS These data represent follow-up of the largest reported series of patients undergoing PCI for
a CTO. The 10-year survival rates for matched non-CTO and the CTO cohorts were similar.
Success rates have continued to improve without an accompanying increase in MACE rates.
A successfully revascularized CTO confers a significant 10-year survival advantage compared
with failed revascularization. (J Am Coll Cardiol 2001;38:409–14) © 2001 by the American
College of Cardiology
Percutaneous coronary intervention (PCI) of a chronic total
coronary artery occlusion (CTO) is now a well-accepted
revascularization procedure accounting for approximately
10% of patients undergoing PCI (1–3). Few large series
have been published on the long-term outcome (4,5).
However, it is unclear whether successfully opening a CTO
is associated with an improved outcome. A previous report
of 354 patients demonstrated only a trend toward improved
survival among those with successful angioplasty of a CTO
(5). Another report (4) demonstrated significantly improved
cardiac survival in a similar cohort of 480 patients. Utilizing
the 20-year experience from the Mid-America Heart Insti-
tute (MAHI), we identified patients who underwent PCI of
a CTO. We present here the in-hospital complication rates,
success rates and long-term clinical outcomes in 2,007
consecutive patients with chronic total occlusions.
METHODS
Study design. Consecutive patients who underwent PCI of
a chronically occluded native coronary vessel between June
1980 to December 1999 were included in this analysis.
Patients were identified as undergoing single versus mul-
tivessel PCI. Multivessel PCI included elective interven-
tions of additional vessels within 30 days of the initial
procedure. Patients with acute occlusions and those with
chronic total occlusion of a saphenous venous graft were not
included in this analysis. Patients were identified using the
MAHI Interventional Registry. Dedicated personnel have
prospectively entered patients into the MAHI Registry. The
registry contains baseline demographics, clinical and proce-
dural characteristics and in-hospital outcomes.
To compare our total CTO cohort with patients who
underwent PCI of nonoccluded stenoses, we applied
propensity-scoring methods to the MAHI Interventional
Registry, of 25,620 patients, so as to identify a matched
non-CTO cohort. Predicted probabilities of CTO were
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estimated using logistic regression on major clinical vari-
ables including diseased vessels, age, unstable angina, prior
revascularization, prior myocardial infarction (MI), date of
procedure and ejection fraction. Both CTO and non-CTO
patients were matched by predictor values described by
D’Agostino (6).
The CTO cohort and non-CTO cohorts were further
stratified into single-vessel (SVP) and multivessel (MVP)
procedures, and subsequently grouped on the basis of a
technically successful procedure. Follow-up information was
obtained through the Social Security Death Index. Long-
term follow-up was available for 93.6% of the CTO cohort,
with a mean follow-up time of 91.4 6 55.4 months.
DEFINITIONS
A CTO was defined as a lesion exhibiting Thrombolysis In
Myocardial Infarction flow grade 0–1 of a native coronary
artery. Patients were excluded if they had sustained an acute
MI within seven days prior to the procedure. Patients were
identified as individuals admitted for PCI. Individuals,
therefore, may be present more than once. Technical success
was defined as the ability to cross the occluded segment with
both a wire and balloon and successfully open the artery
with a ,40% residual stenosis in all views. Procedural
success was defined as a technical success with no in-
hospital major adverse cardiac event (MACE). A CTO
success was defined as a technical success. A MACE was
defined as the occurrence of death, Q-wave MI or urgent
revascularization. Urgent revascularization was classified by
operators caring for patients and required repeat PCI of
target vessel during the same admission or coronary artery
bypass graft surgery (CABG) including bypass of the target
vessel. Routine creatine kinase or creatine kinase-MB frac-
tion data were not routinely collected post-PCI. The MI
component of MACE includes only the Q-wave MI rate.
The non–Q-wave MI rate is presented separately. We
identified both new Q-wave and non–Q-wave MIs. An
SVP was defined as either PCI of the CTO segment only,
or of the CTO segment plus additional lesions of the same
occluded vessel. An MVP encompassed dilation in the
occluded vessel plus dilation of vessels other than the CTO
vessel within 30 days. Repeat percutaneous transluminal
coronary angioplasty (PTCA) was defined as a subsequent
procedure in the occluded vessel.
INTERVENTIONAL TECHNIQUE
Angioplasty was performed using standard over-the-wire
techniques, as previously described (7). The technique has
been modified over time by utilization of second-generation
guide wires, including the Choice PT (Boston Scientific,
Watertown, Massachusetts), Shinobi (Cordis, Miami, Flor-
ida) and Cross-It (Guidant, Santa Clara, California) wires.
Stents were used after PTCA in 7.0% of the cohort. Stented
patients were treated with coumadin for one month until
post-stenting therapy was changed to a thienopyridine
(ticlopidine or clopidogrel) in 1996 (8). All patients were
treated with aspirin indefinitely, and all patients received
heparin at the time of the procedure to achieve an activated
clotting time of 250 to 350 s.
END POINTS AND STATISTICS
The primary end points for this analysis were in-hospital
complications, procedural success rates and 10-year cumu-
lative survival.
A propensity scoring method was used to identify a
non-CTO cohort, matched on the basis of age, ejection
fraction, diseased vessels treated, prior revascularization,
prior MI, unstable angina status and chronological date
treated (9). The propensity score is the estimated probability
of group selection (in this case, of having a CTO). These
scores were obtained using logistic regression, with CTO as
the dependent variable on the selection covariates. By
matching CTO and non-CTO patients with similar pro-
pensity scores, comparable cohorts were obtained having
similar distributions of risk factors.
Data are listed as mean 6 SD. Kaplan-Meier estimates
were used to depict survival and events, and log-rank
analysis was used to compare survival curves (in one case
where survival curves crossed, the Wilcoxon rank-sum test
was used). Continuous variables were analyzed for signifi-
cance by the unpaired Student t test. Discrete variables were
analyzed by chi-square or the Fisher exact test. All statistical
calculations were performed with SAS version 6.12 statis-
tical software. A p value of ,0.05 was considered statisti-
cally significant. Time to all-cause mortality was compared
between CTO success and failure groups using proportional
hazards regression, controlling for major risk factors, includ-
ing ejection fraction, age, diabetes, number of diseased
vessels, creatinine and unstable angina. Adjusted hazard
ratios, 95% confidence intervals and p values are reported.
RESULTS
Baseline demographics. We identified a total of 2,007
patients who underwent PCI of a CTO during the period of
June 1980 to December 1999. The baseline demographics
for this cohort and the matched non-CTO cohort are
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CPK 5 creatine phosphokinase
CTO 5 chronic total coronary artery occlusion
MACE 5 major adverse cardiac event
MAHI 5 Mid-America Heart Institute
MI 5 myocardial infarction
MVP 5 multivessel procedure
PCI 5 percutaneous coronary intervention
PTCA 5 percutaneous transluminal coronary
angioplasty
SVP 5 single-vessel procedure
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shown in Table 1. A significant number of patients had
multivessel disease in both groups. The baseline demo-
graphics for patients with CTO success and failure are
depicted in Table 2. The CTO failure group had a higher
incidence of multivessel disease and prior CABG. There
were 140 patients in this series who underwent an at-
tempted PCI of a CTO more than one time.
Baseline anatomical characteristics. The CTO vessel was
the right coronary artery in 729 (36.3%), the left anterior
descending coronary artery in 752 (37.5%), the left circum-
flex coronary artery in 583 (29.0%) and the left main
coronary artery in 10 (0.5%) patients. The majority of
patients had only one CTO vessel treated (96.3%). One
hundred forty-one patients (7.0%) had coronary stenting of
the CTO segment following PTCA.
Technical and procedural success. The overall technical
and procedural success rates were 72.3% (1,448 of 2,007
patients) and 69.9% (1,403 of 2,007 patients) for the total
CTO cohort. The success rates are improving over time
without an increase in MACE. Linear regression analyses of
success rates over the last 10 years (Fig. 1) demonstrate
improvements in both technical success (slope 1.0%/yr, p 5
0.02, R2 5 49.9%) and procedural success (slope 1.2%/yr,
p 5 0.02, R2 5 51.5%). We found no change in MACE
rates for the same period (slope 20.1%/yr, p 5 0.7).
In-hospital complications. The in-hospital complications
for the CTO and non-CTO cohorts are shown in Table 3.
Total in-hospital MACE rates were similar among the two
Table 1. Baseline Demographics
CTO
(n 5 2,007)
Non-CTO
(n 5 2,007) p Value
Age (yrs) 60.6 6 11.4 60.5 6 11.4 0.7
Women 437 (21.8) 443 (22.1) 0.8
Age .70 yrs 473 (23.6) 475 (23.7) 0.9
Age .80 yrs 72 (3.6) 84 (4.2) 0.3
Diabetes 416 (20.7) 390 (19.4) 0.3
Insulin treatment 156 (7.8) 167 (8.3) 0.5
Hypertension 932 (46.4) 975 (48.6) 0.2
Hyperlipidemia 1158 (58.7) 1140 (58.3) 0.8
Morbid obesity 104 (5.9) 108 (6.2) 0.7
Creatinine .1.5 mg/dl 151 (7.9) 153 (8.1) 0.9
CCS angina class 4 740 (37.0) 768 (38.4) 0.8
Prior AMI 1101 (54.9) 1097 (54.7) 0.9
Prior PCI 721 (35.9) 738 (36.8) 0.6
Prior CABG 357 (17.8) 341 (17.0) 0.5
No. diseased vessels 0.1
1 501 (25.0) 502 (25.0)
2 745 (37.1) 690 (34.4)
3 761 (37.9) 815 (40.6)
EF (%) 51.3 6 13.8 51.7 6 14.6 0.5
LVEF ,40% 312 (22.6) 318 (22.7) 1.0
LVEF ,30% 121 (8.8) 131 (9.3) 0.6
Total no. vessels stented 0.02
0 1787 (89.0) 1720 (85.7)
1 174 (8.7) 229 (11.4)
2 42 (2.1) 53 (2.6)
3 4 (0.2) 5 (0.2)
Data listed as number (percent of group), mean 6 SD.
AMI 5 acute myocardial infarction; CABG 5 coronary artery bypass grafting;
CCS 5 Canadian Cardiovascular Society; CTO 5 chronic total coronary artery
occlusion; EF 5 ejection fraction; LVEF 5 left ventricular ejection fraction; PCI 5
percutaneous coronary intervention; PTCA 5 percutaneous transluminal coronary
angioplasty.
Table 2. Baseline Characteristics for the CTO Success and
Failure Groups
CTO Success
(n 5 1,491)
CTO Failure
(n 5 514) p Value
Age 60.4 6 11.4 61.1 6 11.5 0.3
Women 335 (22.5) 102 (19.8) 0.2
Diabetes mellitus 316 (21.2) 100 (19.5) 0.4
Insulin treatment 120 (8.0) 36 (7.0) 0.4
Hypertension 678 (45.5) 253 (49.2) 0.1
Hyperlipidemia 856 (58.3) 302 (60.2) 0.5
Creatinine .1.5 mg/dl 117 (8.2) 34 (7.1) 0.5
CCS angina class 4 561 (37.8) 178 (34.7) 0.2
Prior MI 834 (55.9) 266 (51.8) 0.1
Prior PCI 543 (36.4) 177 (34.4) 0.4
Prior CABG 246 (16.5) 111 (21.6) 0.009
No. diseased vessels ,0.001
1 407 (27.3) 93 (18.1)
2 550 (36.9) 195 (37.9)
3 534 (35.8) 226 (44.0)
Ejection fraction (%) 51.1 6 13.8 52.0 6 13.7 0.3
CCS 5 Canadian Cardiovascular Society; CTO 5 chronic total coronary artery
occlusion.
Figure 1. Technical success, procedural success and major adverse cardiac
event (MACE) rates since 1990. CTO 5 chronic total coronary artery
occlusion; PCI 5 percutaneous coronary intervention.
Table 3. In-Hospital Complications for CTO and
Non-CTO Cohorts
CTO
(n 5 2,007)
Non-CTO
(n 5 2,007) p Value
Death 27 (1.3) 17 (0.8) 0.13
Q-wave MI 10 (0.5) 12 (0.6) 0.67
Non–Q-wave MI 38 (1.9) 48 (2.4) 0.27
Urgent CABG 15 (0.7) 22 (1.1) 0.25
Urgent Re-PCI 30 (1.5) 40 (2.0) 0.23
Any dissection 357 (17.8) 267 (13.3) ,0.001
CVA 1 (0.01) 3 (0.1) 0.63
Vascular 34 (1.7) 50 (2.5) 0.08
MACE 76 (3.8) 75 (3.7) 0.9
Data listed as number of patients (percent of group).
CABG 5 coronary artery bypass grafting; CTO 5 chronic total coronary artery
occlusion; CVA 5 cerebrovascular accident; MACE 5 major adverse coronary event;
MI 5 myocardial infarction; Re-PCI 5 repeat percutaneous coronary intervention.
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groups (CTO 76 [3.8%], non-CTO 75 [3.7%]). The Q-
wave MI rate was 0.5% compared with 0.6% for the CTO
and non-CTO groups, respectively, p 5 0.6. The non–Q-
wave MI rate was 1.9% compared with 2.4% for the CTO
and non-CTO groups, respectively, p 5 0.2. In-hospital
complications for the CTO success and CTO-failure
groups are shown in Table 4. The in-hospital MACE for
CTO success was 3.2% versus 5.4% for CTO failure, p 5
0.023. The Q-wave MI rate was 0.4% compared with 0.8%
for the CTO success and CTO failed groups, respectively,
p 5 0.3. The non–Q-wave MI rate was 1.5% compared
with 3.1% for the CTO success and CTO failure groups,
respectively, p 5 0.019. To determine the frequency of wire
perforation with new-generation wires, 420 consecutive
patients were identified who underwent a procedure be-
tween 1995 and 1999. We identified four wire perforations,
or an incidence of 1.05%. Two patients had limited perfo-
ration requiring no additional therapy, and two had cardiac
tamponade requiring urgent pericardiocentesis (0.5%). Both
patients survived.
LONG-TERM RESULTS
Survival. Cumulative 10-year survival curves demonstrate a
total CTO cohort survival of 71.2% compared with 71.4%
for the matched non-CTO cohort (p 5 0.9, Fig. 2A).
Patients who had a successful revascularization of the
occluded segment had a significantly higher survival at 10
years compared to the failure group (Fig. 2B, 73.5% vs. 65%,
p 5 0.001). There was no significant difference in 10-year
survival between the CTO success group and the matched
non-CTO success group (Fig. 2B, 73.5% vs. 71.9%, p 5
0.33).
The SVP group of the CTO cohort experienced a
superior 10-year survival when compared with the MVP
group (Fig. 2C, 76.4% vs. 67.8%, p , 0.001). Similar to the
total CTO cohort, the SVP success group had a significant
Table 4. In-Hospital Complications for CTO-Success and
CTO-Failure Cohorts
CTO Success
(n 5 1,491)
CTO Failure
(n 5 514) p Value
Death 15 (1.0) 12 (2.3) 0.024
Q-wave MI 6 (0.4) 4 (0.8) 0.3
Non–Q-wave MI 22 (1.5) 16 (3.1) 0.02
Urgent Re-PCI 29 (1.9) 1 (0.2) 0.005
Any dissection 255 (17.1) 102 (19.8) 0.16
CVA 0 (0.0) 1 (0.2) 0.3
Vascular complications 29 (1.9) 5 (1.0) 0.1
MACE 48 (3.2) 28 (5.4) 0.023
Data listed as number of patients (percent of group).
CTO 5 chronic total coronary artery occlusion; CVA 5 cerebrovascular accident;
MACE 5 major adverse coronary events; MI 5 myocardial infarction; Re-PCI 5
repeat percutaneous coronary intervention.
Figure 2. Cumulative 10-year survival. (A) Chronic total coronary artery occlusion (CTO) versus matched non-CTO cohorts. (B) CTO-success (CTO-S)
versus matched non-CTO success (M-S) versus CTO-failure (CTO-F) groups. (C) Single (SVP) versus multivessel procedures (MVP). (D) Single-vessel
procedure CTO-success (CTO-S) versus SVP matched non-CTO-success (M-S) versus SVP CTO-failure (CTO-F).
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survival benefit compared with the SVP failure group (Fig.
2D, 80.2% vs. 66.5%, p 5 0.0008). Additionally, the SVP
success group had a slightly better 10-year survival than the
SVP matched non-CTO success group (80.2% vs. 74.4%,
p 5 0.02).
Table 5 depicts the significant multivariable predictors of
long-term survival after an attempted PCI of a CTO. After
an adjustment for differences in baseline characteristics for
the CTO success and failure groups, a CTO success
remained a significant independent predictor of long-term
survival.
There were 514 CTO failures. Of these, 64 underwent
CABG within 30 days. The 10-year survival was 71.2%
(CABG) versus 63.9% (no CABG), p 5 0.054 (Fig. 3). The
benefit of CABG for patients in the failed PCI cohort
remained significant following multivariable adjustment
(Table 6).
DISCUSSION
Summary of findings. These data provide long-term
follow-up on the largest series of patients undergoing PCI
for a CTO reported to date. The CTO and matched
non-CTO cohorts had a similar in-hospital MACE and
10-year survival, suggesting that long-term outcome is not
significantly different for patients with a totally occluded
versus a nonoccluded vessel. Of importance, successfully
opening a CTO was associated with an improved 10-year
survival. Successful revascularization of a CTO remained
associated with improved long-term survival even following
multivariable adjustment in this analysis. Further supporting
this concept is the finding that patients undergoing CABG
after a failed PCI have improved survival compared with
those who did not undergo coronary surgery. In addition,
we discovered that the SVP CTO success group had a better
10-year survival than the SVP matched non-CTO success
group. These findings justify an aggressive attempt at PCI
of a CTO in eligible patients.
There was a modest but statistically significant increase in
technical and procedural success rates over the last 10 years.
Importantly, this has not been associated with a concomi-
tant increase in MACE rates. This is probably related to
improved equipment, operator experience and improved
case selection.
Prior studies. There have been few previous reports of
long-term follow-up in large series of CTO patients under-
going PCI. Bell et al. (5) previously reported a trend for an
increase in seven-year survival among 354 patients under-
going a successful angioplasty (82%) compared with a failed
angioplasty (75%). In our larger experience, there was an
82.3% survival with CTO success versus 74.1% with CTO
failure at seven years and 73.5% versus 65% at 10 years
(log-rank p 5 0.001). The survival data of Ivanhoe et al. (4)
in 480 patients parallel that of ours. Cardiac survival at four
years was significantly higher in successfully treated patients
(99%) versus unsuccessfully treated patients (96%).
It was previously suggested (5) that a ceiling of approxi-
mately 70% in procedural success rates had been achieved.
Stone et al. (6) previously reported a procedural success rate
of 72%. These extended data, however, show improvement
over time in both technical and procedural success rates.
Over the last five years, the technical success rates have
averaged 81.9%, and procedural success rates have averaged
78.6%. Furthermore, the MACE rates have not signifi-
cantly changed over the years.
Study limitations. Our analysis is a retrospective study of
prospectively collected data. We are unable to report the
duration of occlusion for the entire CTO cohort. However,
our group previously noted that in 100 consecutive patients,
the mean duration of occlusion was 12 6 20 months, with
Table 5. Multivariable Predictors of Survival After PCI of CTO
Hazard
Ratio
95% Confidence
Limits p Value
CTO success 0.7 0.5–0.8 ,0.0003
Age .70 yrs 1.9 1.5–2.4 ,0.001
EF , 40% 2.1 1.7–2.7 ,0.001
Diabetes mellitus 1.4 1.1–1.8 0.004
2-vessel disease 1.5 1.1–2.2 0.02
3-vessel disease 1.9 1.4–2.7 ,0.001
Creatinine .2.0 mg/dl 2.2 1.3–3.9 0.005
Unstable angina 1.3 1.0–1.6 0.03
CTO 5 chronic total coronary artery occlusion; EF 5 ejection fraction; PCI 5
percutaneous coronary intervention.
Figure 3. Kaplan-Meier event-free survival for patients with a failed
chronic total coronary artery occlusion (CTO) procedure undergoing
coronary artery bypass graft surgery (CABG) within 30 days and those with
failed CTO procedure not undergoing CABG within 30 days.
Table 6. Multivariable Predictors of Survival for Patients
Undergoing CABG After Failed Attempt of CTO
Hazard
Ratio
95% Confidence
Limits p Value
CABG #30 days 0.43 0.2–0.8 0.009
Age $70 yrs 1.9 1.3–2.8 0.0010
EF ,40% 2.2 1.5–3.3 ,0.001
Diabetes 1.3 0.9–2.0 0.17
2-vessel disease 1.4 0.2–2.9 0.3
3-vessel disease 1.8 0.9–3.5 0.11
Unstable angina 1.6 1.1–2.3 0.014
CABG 5 coronary artery bypass graft surgery; CTO 5 chronic total coronary artery
occlusion; EF 5 ejection fraction.
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58% of these occlusions being $1 month old (6). Approx-
imately 10% of patients in this cohort received a stent;
however, 32% of patients received stents since 1995. Thus,
with the low percentage of patients receiving a stent, these
findings cannot be completely extended to current practice
patterns. We did not routinely collect creatine phosphoki-
nase (CPK) data after interventions during the previous 20
years. All electrocardiograms were routinely assessed for
new Q-waves, and CPK levels were obtained when there
was clinical evidence for myocardial necrosis after PCI.
Conclusions. These data highlight a striking survival ad-
vantage among patients with a successfully opened occluded
artery versus those whose procedure was unsuccessful. This
work supports the concept of a time-independent benefit of
reperfusion. These results elucidate the importance of re-
vascularization of a CTO, and they represent long-term
follow-up on the largest reported series of treated chronic
coronary occlusions. Although success rates have continued
to improve over time, attempted revascularization does not
come without complications. The MACE rates, although
constant, were found to be 3.8% overall. With proper
training and by carefully selecting the lesions attempted,
aggressive intervention of a CTO is justified.
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